Title:
USE OF BONE-DERIVED FACTOR RANKL IN PREPARATION OF DRUG OR PHARMACEUTICAL COMPOSITION FOR REGULATING HOMEOSTASIS OF CENTRAL NERVOUS SYSTEM
Document Type and Number:
WIPO Patent Application WO/2023/024339
Kind Code:
A1
Abstract:
The use of bone-derived factor RANKL in the preparation of a drug or pharmaceutical composition for regulating the homeostasis of the central nervous system. With a series of means such as transgenic animals, in-vivo optical imaging, brain slice electrophysiology, optogenetics and pharmacogenetics, neural tracing technology and peripheral metabolic analysis, the target and mechanism of action of bone-derived factor RANKL on the central nervous system in the central nervous system are systematically studied, the neuromolecular mechanism by which bone-derived factor RANKL-RANK related pathways participate in regulating the neural activity is deeply analyzed, and it is found that bone-derived factor RANKL has an important regulatory effect on the maintenance of brain homeostasis and the normal functioning of higher brain function.
More Like This:
Inventors:
YANG FAN (CN)
GAO DASHUANG (CN)
SHAO JIE (CN)
LIU YUNHUI (CN)
GAO DASHUANG (CN)
SHAO JIE (CN)
LIU YUNHUI (CN)
Application Number:
PCT/CN2021/137976
Publication Date:
March 02, 2023
Filing Date:
December 14, 2021
Export Citation:
Assignee:
SHENZHEN INST OF ADV TECH CAS (CN)
International Classes:
A61P25/00; A61K31/551; A61K48/00; A61P19/08
Domestic Patent References:
WO2002024229A1 | 2002-03-28 |
Foreign References:
US20160220639A1 | 2016-08-04 | |||
CN107929753A | 2018-04-20 | |||
CN101845098A | 2010-09-29 | |||
CN101883859A | 2010-11-10 | |||
CN111388654A | 2020-07-10 |
Attorney, Agent or Firm:
BEIJING ZHONG XUN TONG DA INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: